Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
暂无分享,去创建一个
B. Monk | A. Stuckey | Zangdong He | M. Shahin | T. Herzog | D. Cibula | M. Mirza | L. Landrum | B. Slomovitz | D. Chase | I. Boere | L. Gilbert | J. Buscema | F. Raspagliesi | L. Copeland | A. Auranen | B. Pothuri | D. Black | M. Gold | G. Valabrega | E. Zografos | R. Coleman | L. Hanker | C. McCourt | M. Powell | René dePont Christensen | Z. Novak | Sudarshan Sharma | Ashley Stuckey | S. Gill | Min Tian | Shadi Stevens | I. Boere | S. Stevens
[1] M. Mascolo,et al. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives , 2022, International journal of molecular sciences.
[2] N. Vlahos,et al. Current Approaches to the Management of Patients with Endometrial Cancer , 2022, Cancers.
[3] N. Vale,et al. Dostarlimab: A Review , 2022, Biomolecules.
[4] A. Tinker,et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.
[5] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[6] N. Kvarnström,et al. Uterus transplantation for fertility preservation in patients with gynecologic cancer , 2021, International Journal of Gynecological Cancer.
[7] Qi Wang,et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. , 2021, Gynecologic oncology.
[8] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[9] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[10] A. Tinker,et al. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer , 2020, JAMA oncology.
[11] S. Ragg,et al. Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine , 2020, Clinical pharmacology and therapeutics.
[12] P. Tagliaferri,et al. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial. , 2019, Gynecologic oncology.
[13] A. Scarpa,et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] J. Spicer,et al. Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer , 2019, Front. Immunol..
[15] A. Psyrri,et al. Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer , 2019, ESMO Open.
[16] T. Seiwert,et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.
[17] J. McAlpine,et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? , 2018, Gynecologic oncology.
[18] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[19] G. Curigliano,et al. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy , 2017, BioMed research international.
[20] M. Kloor,et al. The Immune Biology of Microsatellite-Unstable Cancer. , 2016, Trends in cancer.
[21] K. Breckpot,et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice , 2014, Oncotarget.
[22] Frank Bretz,et al. Memory and other properties of multiple test procedures generated by entangled graphs , 2013, Statistics in medicine.
[23] Masashi Kato,et al. Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model , 2013, The Journal of Immunology.
[24] E. Jaffee,et al. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. , 2010, Cellular immunology.
[25] H. Andersson,et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel— long‐ term follow‐ up , 2008, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.